OS Therapies Inc Dossier - Source-backed chat

OS Therapies Inc

OSTXNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.12

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.61Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $75.4M

Enterprise Value $75.2M

Shares Outstanding 45.5M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

OS Therapies Inc. (NYSE American: OSTX) is a clinical-stage biopharmaceutical company positioned to address a critical unmet need in osteosarcoma, a rare pediatric bone cancer with no new approved therapies in over 40 years. The company's lead candidate, OST-HER2, has demonstrated statistically significant overall survival (75% vs. 47% historical control) and event-free survival benefits in its Phase 2b trial. With a rolling BLA submission underway and global regulatory alignment achieved for its confirmatory Phase 3 trial, the company is on track for potential accelerated approvals in late 2026. Furthermore, approval could grant the company a highly valuable Priority Review Voucher (PRV), providing substantial non-dilutive funding to secure its long-term financial runway.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$8.92

High · most bullish analyst$13.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5020%

The FDA requests additional clinical data or rejects the surrogate biomarker endpoint, delaying the BLA approval timeline beyond the September 30, 2026 PRV eligibility window. The company fails to secure near-term financing, and its critically low cash reserves ($0.9M as of March 31, 2026) trigger insolvency or severe dilution for existing shareholders.

Base CaseCentral scenario

$13.0050%

OS Therapies successfully completes its clinical BLA module submission and aligns with the FDA, EMA, and MHRA on surrogate biomarker endpoints. The confirmatory Phase 3 trial initiates in Australia in late Q3 2026. The company secures additional bridge financing or non-dilutive tax refunds to sustain operations through the regulatory review period, leading to approval and commercial launch by early 2027.

Bull CaseUpside scenario

$20.0030%

OST-HER2 receives FDA Accelerated Approval in late 2026, triggering the issuance of a Priority Review Voucher (PRV) valued at approximately $150M–$200M. The sale of the PRV completely funds the company's pipeline, including the next-generation tunable Antibody Drug Conjugate (tADC) platform, and eliminates going-concern risks. Conditional approvals are also secured in Europe, the U.K., and Australia, driving rapid global commercialization.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong Phase 2b clinical data demonstrating a 75% overall survival rate at 2.5 years compared to a 47% historical control.
Potential to receive a highly liquid Priority Review Voucher (PRV) upon FDA approval, historically valued at $150M–$205M.
Global regulatory alignment achieved with the EMA, TGA, FDA, and MHRA on the design of the confirmatory Phase 3 trial.
Diversified pipeline potential through the proprietary tunable Antibody Drug Conjugate (tADC) platform and canine osteosarcoma spin-off (OS Animal Health).

Key Investment Risks

Going concern risk with critically low cash reserves ($0.9M as of March 31, 2026) relative to current liabilities ($17.0M).
High reliance on a single clinical asset (OST-HER2) for near-term valuation and regulatory success.
Regulatory execution risk associated with the FDA's acceptance of surrogate biomarker data for accelerated approval.

Thesis Invalidation Triggers

FDA rejection of the rolling BLA submission or refusal to file.
Inability to initiate the confirmatory Phase 3 trial in late Q3 2026 due to funding or operational delays.
Failure to secure immediate capital, leading to insolvency or a highly dilutive restructuring event.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.